Advanced

Cholera Vaccine Use Is Associated With a Reduced Risk of Death in Patients With Colorectal Cancer : A Population-Based Study

Ji, Jianguang LU ; Sundquist, Jan LU and Sundquist, Kristina LU (2018) In Gastroenterology 154(1). p.1-92
Abstract

Background & Aims Cholera toxin can act as a modulator of the immune response with anti-inflammatory effects; it reduces development of colon polyps in mouse models of colorectal cancer (CRC). We performed a population-based study to determine whether, in patients with a diagnosis of CRC, subsequent administration of the cholera vaccine (killed Vibrio cholerae O1 whole cells and recombinant cholera toxin B subunit) affects mortality. Methods We identified patients from the Swedish Cancer Register who were diagnosed with CRC from July 2005 through December 2012. These patients were linked to the Swedish Prescribed Drug Register to retrieve cholera vaccine use. We used Cox regression analysis to calculate the hazard ratio (HR) of... (More)

Background & Aims Cholera toxin can act as a modulator of the immune response with anti-inflammatory effects; it reduces development of colon polyps in mouse models of colorectal cancer (CRC). We performed a population-based study to determine whether, in patients with a diagnosis of CRC, subsequent administration of the cholera vaccine (killed Vibrio cholerae O1 whole cells and recombinant cholera toxin B subunit) affects mortality. Methods We identified patients from the Swedish Cancer Register who were diagnosed with CRC from July 2005 through December 2012. These patients were linked to the Swedish Prescribed Drug Register to retrieve cholera vaccine use. We used Cox regression analysis to calculate the hazard ratio (HR) of death from CRC and overall mortality in patients with post-diagnostic use of cholera vaccine compared with matched controls. Results A total of 175 patients were diagnosed with CRC and given a prescription for the cholera vaccine after their cancer diagnosis. Compared with propensity score-matched controls and adjusted for confounding factors, patients with CRC who received the cholera vaccine had a decreased risk of death from CRC (HR, 0.53; 95% CI, 0.29–0.99) and a decreased risk of death overall (HR, 0.59; 95% CI, 0.37–0.94). The decrease in mortality with cholera vaccination was largely observed, irrespective of patient age or tumor stage at diagnosis or sex. Conclusions In a population-based study, we associated administration of the cholera vaccine after CRC diagnosis with decreased risk of death from CRC and overall mortality.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cohort Study, Colon Cancer, Epidemiology, Immune Regulation, Register-based Study
in
Gastroenterology
volume
154
issue
1
pages
1 - 92
publisher
W B Saunders
external identifiers
  • scopus:85038384002
ISSN
0016-5085
DOI
10.1053/j.gastro.2017.09.009
language
English
LU publication?
yes
id
7812df4c-cc92-400f-81f7-806965a62977
date added to LUP
2018-01-02 14:35:44
date last changed
2018-07-01 04:51:43
@article{7812df4c-cc92-400f-81f7-806965a62977,
  abstract     = {<p>Background &amp; Aims Cholera toxin can act as a modulator of the immune response with anti-inflammatory effects; it reduces development of colon polyps in mouse models of colorectal cancer (CRC). We performed a population-based study to determine whether, in patients with a diagnosis of CRC, subsequent administration of the cholera vaccine (killed Vibrio cholerae O1 whole cells and recombinant cholera toxin B subunit) affects mortality. Methods We identified patients from the Swedish Cancer Register who were diagnosed with CRC from July 2005 through December 2012. These patients were linked to the Swedish Prescribed Drug Register to retrieve cholera vaccine use. We used Cox regression analysis to calculate the hazard ratio (HR) of death from CRC and overall mortality in patients with post-diagnostic use of cholera vaccine compared with matched controls. Results A total of 175 patients were diagnosed with CRC and given a prescription for the cholera vaccine after their cancer diagnosis. Compared with propensity score-matched controls and adjusted for confounding factors, patients with CRC who received the cholera vaccine had a decreased risk of death from CRC (HR, 0.53; 95% CI, 0.29–0.99) and a decreased risk of death overall (HR, 0.59; 95% CI, 0.37–0.94). The decrease in mortality with cholera vaccination was largely observed, irrespective of patient age or tumor stage at diagnosis or sex. Conclusions In a population-based study, we associated administration of the cholera vaccine after CRC diagnosis with decreased risk of death from CRC and overall mortality.</p>},
  author       = {Ji, Jianguang and Sundquist, Jan and Sundquist, Kristina},
  issn         = {0016-5085},
  keyword      = {Cohort Study,Colon Cancer,Epidemiology,Immune Regulation,Register-based Study},
  language     = {eng},
  month        = {01},
  number       = {1},
  pages        = {1--92},
  publisher    = {W B Saunders},
  series       = {Gastroenterology},
  title        = {Cholera Vaccine Use Is Associated With a Reduced Risk of Death in Patients With Colorectal Cancer : A Population-Based Study},
  url          = {http://dx.doi.org/10.1053/j.gastro.2017.09.009},
  volume       = {154},
  year         = {2018},
}